NYSEArca - Delayed Quote USD

Harbor Health Care ETF (MEDI)

25.35

-0.05

(-0.20%)

At close: April 18 at 11:12 AM EDT

Altair Announces Date of First Quarter 2024 Financial Results Conference Call

TROY, Mich., April 18, 2024 (GLOBE NEWSWIRE) -- Altair (Nasdaq: ALTR), a global leader in computational intelligence, will release its financial results for the first quarter ended March 31, 2024, after the market close on Thursday, May 2, 2024. On that day, management will hold a conference call and webcast at 5 p.m. ET to review and discuss the Company’s first quarter 2024 results and second quarter and full year 2024 outlook. A recorded version of this webcast will be available after the call

GlobeNewswire 9 hours ago

ALTR
+0.26%
Genetic Technologies Announces $2 Million Registered Direct Offering

MELBOURNE, Australia, April 19, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, "Company", "GTG", or "Genetic Technologies"), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announced that it has entered into a definitive agreement for the purchase and sale in a registered direct offering of 1,000,000 American Depositary Shares ("ADSs") (or ADS equivalents in lieu thereof), each representing thirty (30) ordinar

GlobeNewswire 13 hours ago

GENE
-22.78%
GNTLF
Jan van Eck Receives 2024 ETF.com Lifetime Achievement Award

NEW YORK, April 18, 2024--VanEck CEO Jan van Eck was last night honored with the Lifetime Achievement Award at the 2024 ETF.com Awards.

Business Wire 15 hours ago

GDX

ANGL
Altair Acquires Cambridge Semantics, Powering Next-Generation Enterprise Data Fabrics and Generative AI

Altair (Nasdaq: ALTR) a global leader in computational intelligence, acquired Cambridge Semantics, a modern data fabric provider and creator of one of the industry's leading analytical graph databases. Cambridge Semantics' graph-powered data fabric technology accelerates the creation of comprehensive enterprise knowledge graphs, integrating the complex web of structured and unstructured enterprise data together into a single, simplified view.

PR Newswire 18 hours ago

ALTR
+0.26%
Amgen (AMGN) Suffers a Larger Drop Than the General Market: Key Insights

Amgen (AMGN) concluded the recent trading session at $264.07, signifying a -0.59% move from its prior day's close.

Zacks yesterday

AMGN
-0.50%
Alkermes to Report First Quarter Financial Results on May 1, 2024

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, May 1, 2024 to discuss the company's first quarter financial results.

PR Newswire yesterday

ALKS
-1.04%
10 Best Commodity ETFs for 2024 Inflation

Almost every major commodity group is outperforming the S&P 500 in 2024.

etf.com yesterday

UGA

USO

DBC
Alkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks yesterday

ALKS
-1.04%
Wall Street Analysts Predict a 45.56% Upside in Ligand (LGND): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 45.6% in Ligand (LGND). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks yesterday

LGNZZ
Gold's Outlook Is as Shiny as the Metal Itself

The upper threshold for gold is still likely a long way off.

etf.com yesterday

DBP

GLD

IAUM
Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor

80% of people diagnosed with anxiety, depression report losing years or decades of timeSALT LAKE CITY, April 17, 2024 (GLOBE NEWSWIRE) -- An astonishing 44% of Americans feel they have lost time in their lives due to poor mental health. That number jumps to nearly 80% for those diagnosed with anxiety and/or depression, according to the latest GeneSight Mental Health Monitor, a nationwide survey from Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine. Of those

GlobeNewswire yesterday

MYGN
-0.70%
New Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomes

MELBOURNE, Australia, April 17, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has established a precision oncology division and announced its highly anticipated portfolio of new diagnostic tests under its geneType precision oncology brand. The proprietary-developed tests will provide invaluable information to medical oncologists,

GlobeNewswire yesterday

GENE
-22.78%
GNTLF
Can This High-Yield Dividend Stock Keep Beating the S&P 500?

Amgen's shares have come under pressure this year, making it a compelling bargain buy.

Motley Fool yesterday

AMGN
-0.50%
^GSPC
Got $5,000? Here Are 3 Undervalued Stocks to Buy and Hold Forever

Not every business in operation today is built to thrive -- or even last -- indefinitely. These are.

Motley Fool yesterday

DAL

AMGN
-0.50%
^GSPC
AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024

Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20, from 9:15-11:15 a.m. PDT.

PR Newswire 2 days ago

AMGN
-0.50%
Here's What's Happening in Markets: April 16

Equity ETFs waver as investors digest earnings and potential rate cuts.

etf.com 2 days ago

QQQ

VESIX

VEUPX
Aptevo (APVO) Stock Plummets 79% in a Week: Here's Why

Aptevo (APVO) plunges after it issues secondary shares, which are not only issued at a significant discount but also substantially dilute the existing shareholder base.

Zacks 2 days ago

ANIP

LGNZZ

ADMA
Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study

Interim results from a late-stage study show that Marinus' (MRNS) ganaxolone failed to meet the pre-specified stopping criteria in patients with refractory status epilepticus.

Zacks 2 days ago

MRNS

ANIP

LGNZZ
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks 2 days ago

ALKS
-1.04%
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen

SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Prenatal Diagnosis has published a study1 demonstrating exceptional positive predictive value (PPV) for 22q11.2 microdeletion screening using Myriad’s prenatal cell-free DNA (pcfDNA) screen, Prequel®, which incorporates fetal fraction amplification. Prior studies from other commercial pcfDNA laboratories have reported a broad range of

GlobeNewswire 2 days ago

MYGN
-0.70%

Performance Overview

Return	MEDI	Category
YTD	+2.39%	+6.33%
1-Year	+21.51%	+11.04%
3-Year	0.00%	-0.38%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Harbor Health Care ETF (MEDI)

Related ETF News

Altair Announces Date of First Quarter 2024 Financial Results Conference Call

Genetic Technologies Announces $2 Million Registered Direct Offering

Jan van Eck Receives 2024 ETF.com Lifetime Achievement Award

Altair Acquires Cambridge Semantics, Powering Next-Generation Enterprise Data Fabrics and Generative AI

Amgen (AMGN) Suffers a Larger Drop Than the General Market: Key Insights

Alkermes to Report First Quarter Financial Results on May 1, 2024

10 Best Commodity ETFs for 2024 Inflation

Alkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Wall Street Analysts Predict a 45.56% Upside in Ligand (LGND): Here's What You Should Know

Gold's Outlook Is as Shiny as the Metal Itself

Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor

New Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomes

Can This High-Yield Dividend Stock Keep Beating the S&P 500?

Got $5,000? Here Are 3 Undervalued Stocks to Buy and Hold Forever

AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024

Here's What's Happening in Markets: April 16

Aptevo (APVO) Stock Plummets 79% in a Week: Here's Why

Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen

Performance Overview